Drug Profile
Mesenchymal stem cell therapy - Longeveron
Alternative Names: Allogeneic Human Mesenchymal Stem Cells; LMSC; Lomecel-B; LOMECEL-B; Longeveron human mesenchymal stem cellsLatest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator Longeveron
- Developer Longeveron; National Heart, Lung and Blood Institute; University of Miami
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Alzheimer's disease; Fatigue; Hypoplastic left heart syndrome
- Phase I/II Dilated cardiomyopathy
- Phase I Metabolic syndrome; SARS-CoV-2 acute respiratory disease
- Clinical Phase Unknown Cognition disorders; Osteoarthritis